Contract awardedMedicines supply

Transitional Drugs 5 for NHS Wales goes to Janssen, Mercury and Teva

NHS Wales Shared Services Partnership bought three medicines that have recently lost exclusivity from Janssen, Mercury Pharmaceuticals and Teva UK Limited. The award came to £5.6m, about an eighth of the £45.1m estimate.

The medicines are aflibercept, dapagliflozin and golimumab. Denosumab was named at the planning stage but left out of the tender. Products had to pass a quality check. Cost then counted for 85% of the score and environmental and social value for 15%.

Nine bids came in to the open tender. The three suppliers were chosen in November 2025, with no split of the value between them. The contract can run to December 2028 with its extension.

Alert me to similar tenders

Contract ends December 2027

What
Medicines supply
Supplier
3 suppliers
Janssen and 2 more
Value
£5.58m
How it was bought
Open
9 bids
Dates and next
Jan 2026 to Dec 2027
Being re-tendered now
Open

Being re-tendered now

Generic Drugs - Oral Liquids · £6.74m · closes 14 Dec 2026

See the live tender

How it was bought

4 official notices
  1. 6 Oct 2025Planning noticeFind a Tender
  2. 16 Oct 2025Tender noticeFind a Tender
  3. 17 Nov 2025Bids closed9 bids
  4. 8 Dec 2025Award noticeFind a Tender
  5. 1 Jan 2026Contract starts
  6. 29 Jan 2026Award noticeFind a Tender
  7. 14 Dec 2026Re-tender openBids dueLive tender
  8. 31 Dec 2027Contract endsUp to Dec 2028 with extension

NHS Wales Shared Services Partnership has bought this 12 or more times since 2021

Typical length
2 years
Typical value
£2.76m
Suppliers used
120
in 12 of its purchases
AwardedContractWon byValue
Sep 2026Locked1 yearLocked£1.6m
Jun 2026Locked2 yearsLocked£16.8m
Jun 2026Locked1.5 yearsLocked£6.53m
Mar 2026Locked1 yearLocked£5.86m
Dec 2025This purchase2 yearsJanssen, Mercury Pharmaceuticals, Teva UK Limited£5.58m

and at least 7 more

Suppliers NHS Wales Shared Services Partnership has used in 12 of its purchases

SupplierContractsValue
Locked7·
Locked7·
Teva UK Limited Won this one6·
Mercury Pharmaceuticals Won this one6·
Janssen Won this one5·

and 115 more

See the contracts and who won them

Figures to 21 November 2026

How it compares

With every medicines supply award since 2021

Half of awards fall between £200,000 and £1.98mMedian £500,000

Awards
438
Firms that won them
277
Median award
£500,000
of 360 with a value
This award
Bigger than 88%
of them
Typical length
2 years
In Wales
40 awards

277 firms have won medicines supply awards since 2021.

RankFirmAwardsValue
1Locked38£6.93m
2Locked33£32.8m
3Teva UK Limited Won this one31£25.6m
4Locked30£146.9m
4Locked30£12.7m
6Locked28£25.6m
18Mercury Pharmaceuticals Won this one19£11.6m
42Janssen Won this one10£108.3m
See who wins this work

Medicines supply at other buyers

NHS Wales Shared Services Partnership has awarded 2,355 contracts since 2021.

See NHS Wales Shared Services Partnership's page
  • Janssen has won 10 public contracts since 2021, 8 or more of them from NHS Wales Shared Services Partnership.

    • Dec 2025This purchase
    • Jun 2025Locked£22.4m
    • Jun 2025Locked£36.2m
    • May 2025Locked£3.03m
    • Mar 2025Locked
    • Jun 2024Locked£1.69m
    • Aug 2023Locked£1.62m
    • Aug 2022Locked£2.29m
    See the contracts
  • Mercury Pharmaceuticals has won 19 public contracts since 2021, 8 or more of them from NHS Wales Shared Services Partnership.

    • Sep 2026Locked
    • Jun 2026Locked
    • Mar 2026Locked
    • Dec 2025This purchase
    • Jun 2025Locked£114,748
    • Jun 2025Locked£157,800
    • Jun 2024Locked£5.82m
    • Jan 2024Locked£917,823
    See the contracts
  • Teva UK Limited has won 31 public contracts since 2021, 8 or more of them from NHS Wales Shared Services Partnership.

    • Sep 2026Locked
    • Mar 2026Locked
    • Dec 2025This purchase
    • Jun 2025Locked£1.91m
    • Jun 2025Locked£6.58m
    • Apr 2025Locked£49,200
    • Jun 2024Locked£1.04m
    • Jun 2024Locked£65,934
    See the contracts

1 medicines supply tender is open now

See it
More medicines supply contracts awarded in 2025